Orbimed Advisors LLC Buys 458,200 Shares of Bicara Therapeutics Inc. $BCAX

Orbimed Advisors LLC raised its position in Bicara Therapeutics Inc. (NASDAQ:BCAX) by 219.1% in the 1st quarter, Holdings Channel.com reports. The fund owned 667,300 shares of the company’s stock after acquiring an additional 458,200 shares during the quarter. Orbimed Advisors LLC’s holdings in Bicara Therapeutics were worth $13,273,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Siren L.L.C. raised its stake in Bicara Therapeutics by 11.2% in the first quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Bicara Therapeutics during the first quarter worth about $2,148,000. Dimensional Fund Advisors LP grew its stake in shares of Bicara Therapeutics by 166.9% during the first quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock worth $2,170,000 after acquiring an additional 68,327 shares during the last quarter. Swiss National Bank increased its holdings in shares of Bicara Therapeutics by 70.3% during the first quarter. Swiss National Bank now owns 55,000 shares of the company’s stock valued at $1,094,000 after acquiring an additional 22,700 shares in the last quarter. Finally, Candriam S.C.A. acquired a new position in shares of Bicara Therapeutics during the first quarter valued at about $4,750,000.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BCAX shares. Morgan Stanley raised their price target on shares of Bicara Therapeutics from $36.00 to $37.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Citizens Jmp reissued a “market outperform” rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Guggenheim assumed coverage on Bicara Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $42.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Finally, HC Wainwright lifted their price target on Bicara Therapeutics from $40.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Stock Performance

Shares of NASDAQ:BCAX opened at $27.02 on Monday. Bicara Therapeutics Inc. has a 12-month low of $9.57 and a 12-month high of $30.99. The business has a 50 day moving average of $24.55 and a two-hundred day moving average of $20.89. The company has a market capitalization of $1.78 billion, a PE ratio of -9.72 and a beta of -0.81.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Equities research analysts predict that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $28.42, for a total value of $284,200.00. Following the sale, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,292,359.84. The trade was a 2.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The stock was sold at an average price of $28.98, for a total value of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 88,450 shares of company stock worth $2,366,675 over the last quarter. 13.80% of the stock is currently owned by corporate insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.